244 related articles for article (PubMed ID: 17296744)
1. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus.
Govorkova EA; Ilyushina NA; Boltz DA; Douglas A; Yilmaz N; Webster RG
Antimicrob Agents Chemother; 2007 Apr; 51(4):1414-24. PubMed ID: 17296744
[TBL] [Abstract][Full Text] [Related]
2. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.
Boltz DA; Rehg JE; McClaren J; Webster RG; Govorkova EA
J Infect Dis; 2008 May; 197(9):1315-23. PubMed ID: 18422444
[TBL] [Abstract][Full Text] [Related]
3. Competitive fitness of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
Govorkova EA; Ilyushina NA; Marathe BM; McClaren JL; Webster RG
J Virol; 2010 Aug; 84(16):8042-50. PubMed ID: 20519385
[TBL] [Abstract][Full Text] [Related]
4. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.
Ilyushina NA; Seiler JP; Rehg JE; Webster RG; Govorkova EA
PLoS Pathog; 2010 May; 6(5):e1000933. PubMed ID: 20523902
[TBL] [Abstract][Full Text] [Related]
5. Effect of an asparagine-to-serine mutation at position 294 in neuraminidase on the pathogenicity of highly pathogenic H5N1 influenza A virus.
Kiso M; Ozawa M; Le MT; Imai H; Takahashi K; Kakugawa S; Noda T; Horimoto T; Kawaoka Y
J Virol; 2011 May; 85(10):4667-72. PubMed ID: 21367898
[TBL] [Abstract][Full Text] [Related]
6. Interactions of oseltamivir-sensitive and -resistant highly pathogenic H5N1 influenza viruses in a ferret model.
Govorkova EA; Ilyushina NA; Marathe BM; McClaren JL; Webster RG
Influenza Other Respir Viruses; 2011 May; 5(Suppl 1):90-3. PubMed ID: 21751467
[No Abstract] [Full Text] [Related]
7. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
[TBL] [Abstract][Full Text] [Related]
8. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model.
Hurt AC; Lowther S; Middleton D; Barr IG
Antiviral Res; 2010 Sep; 87(3):361-6. PubMed ID: 20603155
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses.
Kiso M; Kubo S; Ozawa M; Le QM; Nidom CA; Yamashita M; Kawaoka Y
PLoS Pathog; 2010 Feb; 6(2):e1000786. PubMed ID: 20195462
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model.
Govorkova EA; Ilyushina NA; McClaren JL; Naipospos TS; Douangngeun B; Webster RG
Antimicrob Agents Chemother; 2009 Jul; 53(7):3088-96. PubMed ID: 19349520
[TBL] [Abstract][Full Text] [Related]
11. The Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses.
Paules CI; Lakdawala S; McAuliffe JM; Paskel M; Vogel L; Kallewaard NL; Zhu Q; Subbarao K
J Infect Dis; 2017 Aug; 216(3):356-365. PubMed ID: 28633457
[TBL] [Abstract][Full Text] [Related]
12. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice.
Ilyushina NA; Hay A; Yilmaz N; Boon AC; Webster RG; Govorkova EA
Antimicrob Agents Chemother; 2008 Nov; 52(11):3889-97. PubMed ID: 18725448
[TBL] [Abstract][Full Text] [Related]
13. Airborne transmission of influenza A/H5N1 virus between ferrets.
Herfst S; Schrauwen EJ; Linster M; Chutinimitkul S; de Wit E; Munster VJ; Sorrell EM; Bestebroer TM; Burke DF; Smith DJ; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
Science; 2012 Jun; 336(6088):1534-41. PubMed ID: 22723413
[TBL] [Abstract][Full Text] [Related]
14. Amantadine-oseltamivir combination therapy for H5N1 influenza virus infection in mice.
Ilyushina NA; Hoffmann E; Salomon R; Webster RG; Govorkova EA
Antivir Ther; 2007; 12(3):363-70. PubMed ID: 17591026
[TBL] [Abstract][Full Text] [Related]
15. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses.
Govorkova EA; Leneva IA; Goloubeva OG; Bush K; Webster RG
Antimicrob Agents Chemother; 2001 Oct; 45(10):2723-32. PubMed ID: 11557461
[TBL] [Abstract][Full Text] [Related]
17. Vaccination Is More Effective Than Prophylactic Oseltamivir in Preventing CNS Invasion by H5N1 Virus via the Olfactory Nerve.
Siegers JY; van den Brand JM; Leijten LM; van de Bildt MM; van Run PR; van Amerongen G; Stittelaar KJ; Koopmans MP; Osterhaus AD; Kuiken T; van Riel D
J Infect Dis; 2016 Aug; 214(4):516-24. PubMed ID: 27448390
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.
Govorkova EA; Marathe BM; Prevost A; Rehg JE; Webster RG
Antiviral Res; 2011 Aug; 91(2):81-8. PubMed ID: 21635924
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses.
Takano R; Kiso M; Igarashi M; Le QM; Sekijima M; Ito K; Takada A; Kawaoka Y
J Infect Dis; 2013 Jan; 207(1):89-97. PubMed ID: 23053629
[TBL] [Abstract][Full Text] [Related]
20. Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.
Cardoso FM; Ibañez LI; Van den Hoecke S; De Baets S; Smet A; Roose K; Schepens B; Descamps FJ; Fiers W; Muyldermans S; Depicker A; Saelens X
J Virol; 2014 Aug; 88(15):8278-96. PubMed ID: 24829341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
